These are BsAbs targeting multiple immune checkpoint receptors (such as PDL1-41BB, PD1-LAG3, and PDL1- CTLA-4) or multiple antigens in the tumor cell (such as CD47- CD19 and CD19-CD22). This evidence concerns the gene CD19 and neoplasm.